TEAM

Michael P. Bevilacqua, M.D., Ph.D., Chief Executive Officer and Chief Scientific Officer

Dr. Bevilacqua, co-founder of Amicrobe, brings more than 30 years of experience as a medical scientist, inventor, and business executive. He has led successful research laboratories at Harvard Medical School and as a Howard Hughes investigator at UCSD Medical Center. As VP of Amgen, he built a division for inflammatory and immunological diseases. Dr. Bevilacqua has founded and / or worked with start-up corporations in both therapeutics and diagnostics. His scientific work has led to many patents and publications.

Timothy J. Deming, Ph.D., Consultant

Prof. Deming is a key consultant and co-founder. He has pioneered novel methods for the controlled synthesis of copolypeptides, publishing more than 70 articles and 16 patents. Professor Deming's research utilizes innovative chemistry techniques to synthesize and characterize complex biomaterials based on copolypeptides. He has led successful research programs at UCSB and served as Chair of the UCLA Bioengineering Department, where he is currently a professor.

Carl K. Edwards, III, Ph.D., Director of Preclinical Development

Dr. Edwards has over 20 years R&D experience in leading corporations (Amgen, Marion Merrell Dow, Schering AG, Western States Biopharmaceuticals). At Amgen, he was Clinical Research Project Team Leader for more than five products (two approved by the FDA). At Amicrobe, Dr. Edwards is responsible for designing and executing the development programs to enter first-in-man studies.

Daniel J. Huang, Director of Operations

Mr. Huang oversees internal operations, as well as outside interactions with contract research / manufacturing organizations. He also contributes substantially to R&D project management and business development efforts. Mr. Huang's education and work experience in molecular biology (Occidental College) and data management serve well in his operations role at the interface of science and business.

Joseph S. Solomkin, M.D., Senior Consultant for Surgery and Medicine

Dr. Solomkin is an international leader in scientific and clinical understanding of surgical and post-traumatic infections. He is Professor of Surgery Emeritus at the University of Cincinnati Department of Surgery and founder and Executive Director of the International Surgical Infection Study Group. Dr. Solomkin is regularly involved in guideline projects, including work with the Centers for Disease Control (CDC), Food and Drug Administration (FDA), and World Health Organization (WHO).

 

BOARD OF DIRECTORS

Michael Flesch, Chairman

  • Chair & CEO of Community Asset Management, a private investment company focused in real estate
  • Venture capitalist
  • Former litigation attorney with Brobeck Phleger & Harrison representing primarily fortune 500 companies
  • Served on Finance Committees of UCLA and Investment Committee of Occidental College
  • Member of the UCLA Foundation Board of Directors
  • Serves on corporate boards of NanoPacific Holdings and Bruin Biometrics

Joseph A. Boystak

  • President & CEO Brightwaters Capital, LLC, a private equity investment company
  • Managing Director & CEO Hudson/Brightwaters, a private merchant bank
  • Managing Director and Senior investment banker with 25 years of experience with major Wall Street firms - Jefferies & Co., Tucker Anthony Sutro and Dean Witter Reynolds
  • Executed over $15 Billion of transactions domestically and internationally
  • Focus on life sciences, nanotechnology, and clean technology
  • Serves on the boards of NanoPacific Holdings, Bruin Biometrics, Exosome Diagnostics, The Johns Hopkins Bloomberg School of Public Health and The UCLA Foundation Board of Governors

Albert Carnesale, Ph.D.

  • UCLA Chancellor Emeritus and Professor in the School of Public Affairs and Henry Samueli School of Engineering and Applied Science
  • Former UCLA Chancellor
  • Former Harvard University Provost
  • Member of U.S. Government delegations to Strategic Arms Limitation Talks (SALT, 1969-72) and International Nuclear Fuel Cycle Evaluation (INFCE,1978-80)
  • Former Senior Engineer, Nuclear Division, Martin Marietta Corp.
  • Fellow, American Association for the Advancement of Science
  • Fellow, American Academy of Arts and Sciences
  • Chairs and has chaired several committees at the National Academy of Sciences
  • Member, Blue Ribbon Commission on America’s Nuclear Future
  • Member of the National Academy of Engineering

Michael P. Bevilacqua, M.D., Ph.D. (see above)